Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. (MGRX) operates at the intersection of telemedicine and men's wellness, providing innovative health solutions through its digital platform. This news hub offers investors and industry observers centralized access to official corporate developments and market insights.
Track all essential updates including quarterly earnings disclosures, new product launches, strategic partnerships, and regulatory milestones. Our curated collection ensures timely access to press releases and verified news affecting MGRX's position in the competitive telehealth sector.
The resource prioritizes factual reporting on operational expansions, clinical developments, and technological advancements within Mangoceuticals' men's health focus areas. Users can monitor updates related to prescription fulfillment services, digital platform enhancements, and emerging wellness product lines.
Bookmark this page for streamlined tracking of MGRX's progress in revolutionizing men's healthcare through telemedicine. Return regularly to maintain current awareness of developments impacting the company's market presence and industry leadership.
MangoRx has announced the upcoming release of MOJO, a new oral dissolvable tablet aimed at treating low testosterone and male hormone imbalances. The product will combine Enclomiphene Citrate, Pregnenolone, and DHEA, and will be marketed to younger males as a $199 monthly subscription. MOJO is designed to stimulate natural testosterone production and support overall hormonal balance, offering a complementary alternative to MangoRx's existing PRIME Testosterone Replacement Therapy. The launch is scheduled before the end of Q2 2024, with the company aiming to capture a significant share of the growing testosterone replacement therapy market, projected to reach $2.9 billion by 2032.
Mangoceuticals announced the completion of its first batch of Mango ED oral dissolvable tablets (ODTs) for the Mexican and Latin American markets. These tablets, containing Tadalafil, will undergo tests in the U.S. for quality assurance. The next phase includes producing three additional lots for bioequivalence and stability testing in Mexico to meet COFEPRIS standards. This effort is in collaboration with Emifarma. The ED market in Mexico is valued at $216 million annually, growing at 4% per year. MangoRx aims to expand into other LATAM countries post-COFEPRIS certification.
MangoRx, a company specializing in men’s health and wellness products, announced a partnership with Crakmedia, an international performance marketing company. Crakmedia will spearhead MangoRx's digital marketing initiatives, utilizing their extensive experience in performance marketing, web development, and traffic monetization. Digital ads on Crakmedia's network reach up to 1.5 billion views daily across 150 countries. This collaboration aims to boost MangoRx's sales and market presence significantly. MangoRx will benefit from Crakmedia's 15 years of expertise, AI-driven compliance systems, and industry accolades. This partnership is expected to enhance MangoRx's ability to attract new customers and expand its product portfolio.
MangoRx, a men's health and wellness company, has announced the development of oral formulations of Semaglutide and Tirzepatide, branded as 'Slim' and 'Trim.' These drugs, traditionally available as injectables, are designed to aid in weight management. Clinical trials have shown impressive weight loss results, with Semaglutide yielding a 15.2% weight loss and Tirzepatide 15.7% over one year. The GLP-1 receptor agonists' market is projected to reach $164 billion by 2032. MangoRx's oral versions are expected to capture a significant market share due to patient preference for oral medications. The products will be available on MangoRx's telemedicine platform by Q3 2024, priced at $299/month for 'Slim' and $399/month for 'Trim.'
MangoRx (NASDAQ: MGRX) reported a 108% revenue growth in Q1 2024, increasing from $100,000 to $214,000 compared to Q1 2023. This growth is driven by strategic advances in customer acquisition, including the launch of a direct-to-clinic sales division. This allows medical professionals to prescribe MangoRx products directly, reducing customer acquisition costs. The company also acquired a global patent portfolio valued at $35 million for $20 million, aiming to launch non-pharmaceutical products starting with clinical trials in Q3 2024. MangoRx continues to expand its men's health and wellness product line, leveraging a unique telemedicine platform for seamless patient experience.
Mangoceuticals, Inc. (NASDAQ: MGRX) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. The company must reach a bid price of $1.00 per share for ten consecutive days to avoid delisting. Additionally, the 2024 Annual Meeting of Stockholders is scheduled for June 17, 2024.
FAQ
What is the current stock price of Mangoceuticals (MGRX)?
What is the market cap of Mangoceuticals (MGRX)?
